View Older Stories View More Recent Stories

May 7, 2026 04:15PM CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
Apr 30, 2026 08:00AM CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Mar 16, 2026 07:05AM CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
Mar 16, 2026 07:01AM CytomX reports positive phase 1 data for colorectal cancer treatment
Mar 16, 2026 07:00AM CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
Mar 4, 2026 08:00AM CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
Feb 4, 2026 08:00AM CytomX Therapeutics to Present at Upcoming February Conferences
Jan 8, 2026 08:00AM CytomX Therapeutics Announces Business Update and Company Milestones for 2026
Nov 25, 2025 08:00AM CytomX Therapeutics to Present at Upcoming December Investor Conferences
Nov 13, 2025 08:00AM CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
Nov 6, 2025 04:10PM CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Nov 4, 2025 09:15AM CytomX to present CX-801 phase 1 biomarker data at SITC meeting
Nov 4, 2025 09:15AM CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 30, 2025 08:00AM CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
Oct 20, 2025 04:05PM CytomX Therapeutics names Rachael Lester chief business officer
Oct 20, 2025 04:05PM CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
Aug 28, 2025 08:00AM CytomX Therapeutics to Present at Upcoming September Investor Conferences
Aug 13, 2025 08:00AM CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
Aug 7, 2025 04:10PM CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
Jul 31, 2025 08:00AM CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
May 29, 2025 08:00AM CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
May 19, 2025 08:02AM CytomX Therapeutics (CTMX) Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA
May 19, 2025 08:00AM CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
May 12, 2025 06:49AM CytomX Therapeutics (CTMX) Reports Positive Interim Data From Phase 1 Dose Escalation Study of CX-2051
May 12, 2025 06:15AM CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)
May 12, 2025 06:15AM CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
May 5, 2025 08:00AM CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
Apr 28, 2025 04:00PM CytomX Therapeutics (CTMX) Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna
Apr 28, 2025 04:00PM CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting
Mar 6, 2025 04:10PM CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update
Mar 5, 2025 08:00AM CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
Feb 27, 2025 08:00AM CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Jan 8, 2025 08:00AM CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jan 6, 2025 04:05PM CytomX Therapeutics (CTMX) Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
Jan 6, 2025 04:05PM CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
Nov 27, 2024 08:00AM CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
Nov 7, 2024 04:10PM CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Oct 31, 2024 08:00AM CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
Sep 9, 2024 08:00AM CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
Sep 4, 2024 08:00AM CytomX Therapeutics to Present at Upcoming September Investor Conferences
Aug 8, 2024 04:10PM CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Aug 1, 2024 08:00AM CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
Jun 18, 2024 08:00AM CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
Jun 17, 2024 04:15PM CytomX Therapeutics (CTMX) Appoints Chris Ogden as CFO
Jun 17, 2024 04:15PM CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
May 22, 2024 04:05PM CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
May 16, 2024 04:15PM CytomX Therapeutics Announces New Employment Inducement Grants
May 8, 2024 04:10PM CytomX Therapeutics (CTMX) Reports Positive Phase 1a Dose Escalation Data for Monotherapy CX-904
May 8, 2024 04:10PM CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024 04:10PM CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
View More Recent Stories View Older Stories